ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Recurrent somatic mutations in ETNK1 are found in myeloid malignancies.
• These mutations lead to reduced Ethanolamine-Kinase-1 enzymatic activity.

Purpose of the Study:

• To investigate the functional consequences of mutated ETNK1 in myeloid malignancies.
• To elucidate the role of phosphoethanolamine in regulating mitochondrial activity and DNA damage.

Main Methods:

• Analysis of primary leukemic cells and cell lines with mutated ETNK1.
• Assessment of mitochondrial activity, reactive oxygen species (ROS) production, and Histone H2AX phosphorylation.
• Investigation of phosphoethanolamine's interaction with mitochondrial complex II.

Main Results:

• Mutated ETNK1 significantly increases mitochondrial activity, ROS production, and DNA damage.
• Reduced intracellular phosphoethanolamine leads to mitochondrial hyperactivation and DNA damage.
• Phosphoethanolamine directly competes with succinate at mitochondrial complex II.

Conclusions:

• Mutated ETNK1 drives increased mutation accumulation in myeloid malignancies.
• Phosphoethanolamine acts as a negative regulator of mitochondrial activity.
• Therapeutic restoration of phosphoethanolamine can counteract mitochondrial dysfunction and DNA damage.